1. TLSA withdrew its proposed public offering due to unfavorable market conditions. 2. Intranasal foralumab shows promise for treating neuroinflammatory diseases. 3. Foralumab's safety profile recognized in clinical trials with multiple sclerosis patients. 4. The company continues to innovate with patented drug delivery technologies. 5. Market uncertainties pose risks to TLSA's future performance.
FAQ
Why Bearish?
The withdrawal of a public offering may signal reduced investor confidence and financial pressures, akin to similar biotech scenarios where funding difficulties led to stock declines.
How important is it?
The article discusses significant company developments that could influence investor sentiment and stock price, particularly around funding and product development.
Why Short Term?
Short-term reactions from investors to news about fundraising difficulties typically influence stock prices swiftly, particularly in biotech.
Tiziana Life Sciences (TLSA) Withdraws Proposed Public Offering Amid Market Fluctuations
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a pioneering biotechnology company focused on developing innovative immunomodulation therapies, has announced the withdrawal of its proposed public offering of common shares. This decision was influenced by current market conditions, underscoring the challenges that can affect financial strategies in the biotech sector.
Details of the Withdrawal
The announcement specified that the withdrawal of the proposed offering does not constitute an offer to sell or a solicitation of an offer to buy. Additionally, there will be no sale of these securities in any state or jurisdiction where such actions would be unlawful prior to proper registration or qualification under local securities laws.
About Tiziana Life Sciences
Based in Boston, Tiziana Life Sciences specializes in the development of groundbreaking therapies employing advanced drug delivery technologies to facilitate alternative immunotherapy routes. The Company's flagship candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody currently under clinical development. This innovative treatment has shown promise in terms of safety and clinical efficacy, setting it apart in a competitive landscape.
- Intranasal Foralumab: The only fully human anti-CD3 mAb in clinical development.
- Favorable Safety Profile: Extensively demonstrated in clinical studies.
- Patent Portfolio: Numerous patents covering alternative immunotherapy methods, with several applications pending.
Key Insights on Foralumab Development
Foralumab has been examined for its potential to stimulate T regulatory cells through intranasal dosing. Currently, the therapy is being assessed in an open-label intermediate-sized Expanded Access Program involving 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS). Results indicate either improvement or stability of the disease in all participants within six months.
Moreover, Foralumab is undergoing evaluation in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial for non-active secondary progressive multiple sclerosis (NCT06292923). This research positions foralumab as a unique contender not only for the treatment of multiple sclerosis but potentially for other neuroinflammatory and neurodegenerative diseases.
Forward-Looking Statements
Tiziana Life Sciences emphasizes that certain statements in this announcement are forward-looking and are not historic facts. Terms such as 'anticipates,' 'expects,' and 'plans' indicate these statements. The company advises stakeholders not to place undue reliance on these projections due to various risks and uncertainties.
Investors are encouraged to review the 'Risk Factors' section in Tiziana's Annual Report on Form 20-F for the fiscal year ended December 31, 2024, which outlines additional considerations and uncertainties that may impact the company's future performance.
Contact Information
For further information, Tiziana Life Sciences can be contacted via:
Paul Spencer, Business Development and Investor Relations
Phone: +44 (0) 207 495 2379
Email: info@tizianalifesciences.com